MRNA Dec 2026 65.000 call
| Previous close | 97.70 |
| Open | 98.00 |
| Bid | 78.00 |
| Ask | 87.00 |
| Strike | 65.00 |
| Expiry date | 2026-12-18 |
| Day's range | 97.70 - 98.00 |
| Contract range | N/A |
| Volume | |
| Open interest | 3 |
Simply Wall St.Insiders At Moderna Sold US$3.3m In Stock, Alluding To Potential Weakness
In the last year, many Moderna, Inc. ( NASDAQ:MRNA ) insiders sold a substantial stake in the company which may have...
Investor's Business DailyIs Moderna Stock A Buy After Its Second-Ever Product Snags FDA Approval?
Moderna stock is trading sideways despite a bevy of news, including FDA approval for its RSV vaccine. Is MRNA stock a buy right now?
BenzingaCovid-19 Pharma Stars Continue Their Quest To Set New Standards In Cancer Treatment
AstraZeneca PLC (NASDAQ: AZN) kicked off the week by receiving approval from the U.S. Food and Drug Administration for its blockbuster cancer drug Imfinzi combined with chemotherapy being used as a treatment forpatients suffering from specific type of endometrial cancer. Its pharma peer, BioNTech SE (NASDAQ: BNTX) wasn’t as lucky as also on Monday, the FDA put its experimental cancer drug study on partial clinical hold. Combining Immunotherapy And Chemotherapy Is Emerging As A New Standard In Ca
